PIERI, LISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.716
EU - Europa 5.335
AS - Asia 2.089
SA - Sud America 285
Continente sconosciuto - Info sul continente non disponibili 109
AF - Africa 60
OC - Oceania 51
Totale 14.645
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.631
PL - Polonia 2.220
RU - Federazione Russa 1.093
IT - Italia 848
SG - Singapore 551
CN - Cina 426
HK - Hong Kong 334
SE - Svezia 271
IE - Irlanda 270
VN - Vietnam 266
BR - Brasile 220
KR - Corea 179
DE - Germania 141
FR - Francia 115
FI - Finlandia 105
GB - Regno Unito 85
IN - India 77
CH - Svizzera 76
CA - Canada 60
AU - Australia 49
JP - Giappone 42
BD - Bangladesh 32
TR - Turchia 32
ID - Indonesia 30
JO - Giordania 22
UA - Ucraina 21
AE - Emirati Arabi Uniti 20
IQ - Iraq 18
ES - Italia 17
NL - Olanda 17
AR - Argentina 15
BE - Belgio 14
CO - Colombia 14
AT - Austria 13
CI - Costa d'Avorio 12
PK - Pakistan 12
EC - Ecuador 11
ZA - Sudafrica 11
MX - Messico 9
EG - Egitto 8
MA - Marocco 8
PE - Perù 6
NP - Nepal 5
PH - Filippine 5
PY - Paraguay 5
SA - Arabia Saudita 5
UY - Uruguay 5
VE - Venezuela 5
CL - Cile 4
DZ - Algeria 4
IR - Iran 4
KE - Kenya 4
RO - Romania 4
TN - Tunisia 4
UZ - Uzbekistan 4
AL - Albania 3
AZ - Azerbaigian 3
IL - Israele 3
JM - Giamaica 3
LT - Lituania 3
NG - Nigeria 3
SV - El Salvador 3
BB - Barbados 2
BG - Bulgaria 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
KZ - Kazakistan 2
MQ - Martinica 2
MY - Malesia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PT - Portogallo 2
QA - Qatar 2
RS - Serbia 2
SC - Seychelles 2
TH - Thailandia 2
TW - Taiwan 2
AO - Angola 1
EE - Estonia 1
ET - Etiopia 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
KG - Kirghizistan 1
KH - Cambogia 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MU - Mauritius 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
UG - Uganda 1
Totale 14.536
Salva come PNG Salva come JPEG
Città #
Warsaw 2.214
Santa Clara 1.306
Fairfield 749
Ashburn 723
Singapore 349
Woodbridge 330
Seattle 308
Chandler 279
Hong Kong 273
Dublin 269
Houston 260
Cambridge 246
Wilmington 246
San Jose 221
Seoul 172
Ann Arbor 148
Milan 136
Beijing 117
Altamura 109
Lawrence 108
Florence 87
Ho Chi Minh City 87
Princeton 81
Rome 77
Boston 75
Bern 72
Buffalo 70
Council Bluffs 68
Hanoi 66
Lauterbourg 60
Dallas 58
New York 55
Jacksonville 54
Los Angeles 53
Mumbai 48
Munich 48
Moscow 44
San Diego 39
Melbourne 34
Phoenix 34
Boardman 32
The Dalles 31
Dong Ket 30
Helsinki 30
Shanghai 29
Bremen 28
Jakarta 24
Hefei 23
São Paulo 23
Izmir 22
Medford 21
Paris 20
Tokyo 20
Abu Dhabi 19
London 18
Chicago 17
Montreal 16
Turin 16
Clifton 15
Figino 15
Naples 15
Norwalk 15
Redondo Beach 15
Kent 14
Frankfurt am Main 13
Abidjan 12
Bologna 12
Brussels 12
Sydney 12
Vienna 12
Guangzhou 11
Toronto 11
Turku 11
Barcelona 10
Denver 10
Hillsboro 10
Brescia 9
Dearborn 9
Orem 9
Palermo 9
Toyooka 9
Brooklyn 8
Da Nang 8
Andover 7
Brasília 7
Haiphong 7
Manchester 7
Pune 7
Rio de Janeiro 7
San Francisco 7
Tianjin 7
Waltham 7
Alexandria 6
Amsterdam 6
Atlanta 6
Miano 6
Parnaiba 6
Poplar 6
Słupsk 6
Venice 6
Totale 10.589
Salva come PNG Salva come JPEG
Nome #
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 454
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 395
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 349
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 337
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 335
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 335
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 326
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis 318
Imaging studies in extramedullary hematopoiesis of the spleen 315
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. 309
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis 308
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 306
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 303
Chronic myeloproliferative neoplasms: a collaborative approach. 302
Study of new molecular alterations on Philadelphia-negative chronic myeloproliferative neoplasms 299
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 288
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 281
MPN Score 267
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 251
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 230
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 220
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 200
Mutations and prognosis in primary myelofibrosis. 199
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 196
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 193
Treatment options for essential thrombocythemia and polycythemia vera 192
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 191
Fractures needing orthopaedic surgery in haemophilic patients: long-term experience of a dedicated team at a single institution 189
BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques 187
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients 187
Concomitant occurrence of BCR-ABL and JAK2V617F mutation. 186
Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience 184
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. 183
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. 182
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis 177
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. 176
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 174
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. 174
Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis 173
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 172
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 171
The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. 170
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 167
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 167
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis 163
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. 162
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 162
Prognotic Impact of Mutations in Systemic Mastocytosis 159
Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome. 156
Risk of second cancers in chronic myeloproliferative neoplasms. 156
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 154
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study. 154
Low bone mass and hypovitaminosis D in haemophilia: A single-centre study in patients with severe and moderate haemophilia A and B 154
Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. 152
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. 149
Mastocitosi: approccio multidisciplinare a una patologia misconoscciuta 148
Risk of second cancers in chronic myeloproliferative neoplasms 147
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation 142
Rationale for combination therapies in myelofibrosis 139
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. 136
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results 130
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. 129
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome 128
Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis. 120
Masked polycythemia vera (mPV): results of an international study. 118
Policitemia Vera. per conoscerla meglio. 116
The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics. 115
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. 114
Percorsi diagnostici-terapeutici per le neoplasie mieloproliferative nella AOU Careggi 109
Major Orthopaedic Surgery in Persons with Haemophilia A with and without Inhibitors Treated by Emicizumab: A Mid-Term, Large, and Successful Series at a Single Center 108
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. 107
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients 73
Is pharmacological thromboprophylaxis necessary in persons with haemophilia undergoing major orthopaedic surgery? 64
Impaired platelet function in Hermansky-Pudlak syndrome associated with novel mutations in HPS3, HPS6 and HPS8 genes 53
null 10
Totale 14.645
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.523
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.523
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022426 0 0 48 16 13 19 20 39 27 26 76 142
2022/20231.353 121 289 68 111 94 216 160 66 102 15 34 77
2023/2024519 16 46 76 22 46 72 17 110 10 31 46 27
2024/20253.372 90 319 210 478 1.063 522 71 121 205 86 96 111
2025/20263.255 387 404 215 187 345 127 403 155 200 210 120 502
2026/2027363 151 72 140 0 0 0 0 0 0 0 0 0
Totale 14.645